U.S. markets closed

Mirati Therapeutics, Inc. (MRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
190.58+9.58 (+5.29%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close181.00
Open182.40
Bid169.69 x 1300
Ask250.00 x 800
Day's Range176.50 - 192.61
52 Week Range66.01 - 249.42
Volume574,495
Avg. Volume433,570
Market Cap9.65B
Beta (5Y Monthly)1.48
PE Ratio (TTM)N/A
EPS (TTM)-7.96
Earnings DateMay 05, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est247.91
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 15 Fastest Growing Biotech Companies in the US
    Insider Monkey

    15 Fastest Growing Biotech Companies in the US

    In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living […]

  • Mirati Therapeutics To Present At Upcoming Healthcare Conferences
    PR Newswire

    Mirati Therapeutics To Present At Upcoming Healthcare Conferences

    Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, will participate in two upcoming healthcare conferences.

  • MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors
    PR Newswire

    MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors

    The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.